inflammation and glp 1 Incretins as Multi–Disease State Treatments Glucagon-like peptide 1(GLP-1) receptor agonists

Exendin-4 (exenatide) became the first clinically-approved GLP-1R agonist (2005) for treatment of T2D

Presented for research literature review only Bin Dayel FF (2025)

People with the disorder often struggle to resist behaviors that deliver a quick dopamine hit, but some patients say GLP-1s appear to be helping curb those urges

Well create a personalized treatment plan to ensure natural-looking, gradual, and lasting results

When administering the injection, deliver the solution slowly and steadily , then pause for a few seconds before withdrawing the needle

In the SURMOUNT trials, night sweats were more common during dose escalation phases (when patients moved from 2.5 mg to 5 mg to 10 mg weekly injections) rather than at maintenance doses